NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109173&from=3 CLASS PERIO ...

Core Viewpoint - Edwards Lifesciences Corporation is facing a federal securities class action due to allegations of misleading statements regarding its revenue expectations for the fiscal year 2024, particularly concerning its Transcatheter Aortic Valve Replacement (TAVR) platform [3][4]. Group 1: Legal Action and Claims - Faruqi & Faruqi, LLP is investigating potential claims against Edwards and has set a deadline of December 13, 2024, for investors to seek the role of lead plaintiff in the class action [2]. - The complaint alleges that Edwards and its executives violated federal securities laws by failing to disclose material information about the expected revenue growth of TAVR [3]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year [4]. - Following the announcement, Edwards' stock price plummeted from $86.95 per share to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in one day [5]. Group 3: Company Strategy and Market Dynamics - The company attributed the TAVR revenue setback to increased competition from new structural heart therapies, which strained hospital workflows and led to underutilization of TAVR [4]. - Edwards announced three acquisitions during Q2 2024 aimed at enhancing its treatment alternatives to TAVR, indicating a strategic pivot in response to the challenges faced by the TAVR platform [4].

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024. Edwards is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions. For more information, submit a form, ...

LOS ANGELES, Oct. 21, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging misrepresentations related to its Transcatheter Aortic Valve Replacement platform and market demand [2]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Central District of California on behalf of investors who purchased Edwards securities between February 6, 2024, and July 24, 2024 [2]. - Allegations include violations of the Securities Exchange Act of 1934, with claims that Edwards misrepresented its commitment to the Transcatheter Aortic Valve Replacement platform and its ability to engage untreated patients [2]. Group 2: Legal Representation and Actions - Investors wishing to serve as lead plaintiffs must file necessary documents by December 13, 2024, although participation as a class member does not require this [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [3].

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that the company failed to reach the low-treatment-rate population and that healthcare organizations prioritized other treatments [2]. - On July 24, 2024, Edwards Lifesciences reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for TAVR in fiscal Q2 2024, leading to a 31% decline in stock price from $86.95 to $59.70 per share [3]. Group 2: Company Background - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, categorizing its products into four main areas: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart therapies, and Critical Care therapies [2].

SAN DIEGO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charg ...

Group 1 - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that patient activation activities were ineffective and that healthcare organizations prioritized other treatments [2][3] - Following a significant reduction in TAVR guidance and disappointing financial results announced on July 24, 2024, Edwards' stock price dropped by 31%, from $86.95 to $59.70 per share [3] Group 2 - Investors in Edwards Lifesciences are encouraged to seek legal options and submit their information to the law firm representing the case, with no upfront costs for shareholders [4] - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved notable recoveries in past cases, including over $900 million from Tesla, Inc. [4]

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is Dece ...